FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891818168> ?p ?o ?g. }

• W2891818168 endingPage "3133" @default.
• W2891818168 startingPage "3126" @default.
• W2891818168 abstract "Purpose There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)–based gene expression signature (GS) predictive of sensitivity to LCL161, inhibitor of apoptosis antagonist, was translated into a clinical assay and evaluated in a neoadjuvant trial. Patients and Methods Women with localized TNBC (T2/N0–2/M0) were prospectively stratified by GS status and randomly assigned (1:1) to receive oral LCL161 (1,800 mg once per week) and intravenous paclitaxel (80 mg/m 2 once per week; combination arm) or paclitaxel alone (control arm) for 12 weeks, followed by surgery. The primary objective was to determine whether neoadjuvant LCL161 enhances efficacy of paclitaxel, defined by > 7.5% increase in the pathologic complete response (pCR, breast) rate, stratified by GS. Results Of 209 patients enrolled (207 with valid GS scores), 30.4% had GS-positive TNBC. In the GS-positive group, pCR was higher in the combination versus the control arm (38.2% v 17.2%), with 88.8% posterior probability of > 7.5% increase in pCR. However, in the GS-negative group, the pCR was lower in the combination group (5.6% v 16.4%), with 0% posterior probability of > 7.5% increase in pCR. A higher incidence of grade 3 or 4 adverse events in the combination arm included neutropenia (24.5%) and diarrhea (5.7%). Overall, 19 patients (18.1%) in the combination arm discontinued treatment because of adverse events, including pyrexia (n = 5), pneumonia (n = 4), and pneumonitis (n = 4), versus five patients (4.9%) in the control arm. Conclusion This neoadjuvant trial provides evidence supporting a biomarker-driven targeted therapy approach for selected patients with GS-positive TNBC and demonstrates the utility of a neoadjuvant trial for biomarker validation and drug development, but also highlights toxicity risk. Future neoadjuvant clinical trials should carefully weigh these considerations for targeted therapy development in biomarker-defined TNBC." @default.
• W2891818168 created "2018-09-27" @default.
• W2891818168 creator A5000498585 @default.
• W2891818168 creator A5005439813 @default.
• W2891818168 creator A5009653018 @default.
• W2891818168 creator A5011012477 @default.
• W2891818168 creator A5012681954 @default.
• W2891818168 creator A5015970851 @default.
• W2891818168 creator A5016153923 @default.
• W2891818168 creator A5026459010 @default.
• W2891818168 creator A5027981189 @default.
• W2891818168 creator A5034972183 @default.
• W2891818168 creator A5043658324 @default.
• W2891818168 creator A5045301167 @default.
• W2891818168 creator A5050250195 @default.
• W2891818168 creator A5051629490 @default.
• W2891818168 creator A5052487618 @default.
• W2891818168 creator A5058180553 @default.
• W2891818168 creator A5062581318 @default.
• W2891818168 creator A5068059897 @default.
• W2891818168 creator A5069170386 @default.
• W2891818168 creator A5069182089 @default.
• W2891818168 date "2018-11-01" @default.
• W2891818168 modified "2023-10-18" @default.
• W2891818168 title "Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial" @default.
• W2891818168 cites W1999008313 @default.
• W2891818168 cites W1999660608 @default.
• W2891818168 cites W2008181517 @default.
• W2891818168 cites W2025644430 @default.
• W2891818168 cites W2048059530 @default.
• W2891818168 cites W2048931482 @default.
• W2891818168 cites W2052874737 @default.
• W2891818168 cites W2064044903 @default.
• W2891818168 cites W2086064725 @default.
• W2891818168 cites W2096745115 @default.
• W2891818168 cites W2108410268 @default.
• W2891818168 cites W2115961074 @default.
• W2891818168 cites W2117692326 @default.
• W2891818168 cites W2127287298 @default.
• W2891818168 cites W2142022669 @default.
• W2891818168 cites W2147744317 @default.
• W2891818168 cites W2165936545 @default.
• W2891818168 cites W2471493685 @default.
• W2891818168 cites W2474664935 @default.
• W2891818168 doi "https://doi.org/10.1200/jco.2017.74.8392" @default.
• W2891818168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30235087" @default.
• W2891818168 hasPublicationYear "2018" @default.
• W2891818168 type Work @default.
• W2891818168 sameAs 2891818168 @default.
• W2891818168 citedByCount "48" @default.
• W2891818168 countsByYear W28918181682017 @default.
• W2891818168 countsByYear W28918181682019 @default.
• W2891818168 countsByYear W28918181682020 @default.
• W2891818168 countsByYear W28918181682021 @default.
• W2891818168 countsByYear W28918181682022 @default.
• W2891818168 countsByYear W28918181682023 @default.
• W2891818168 crossrefType "journal-article" @default.
• W2891818168 hasAuthorship W2891818168A5000498585 @default.
• W2891818168 hasAuthorship W2891818168A5005439813 @default.
• W2891818168 hasAuthorship W2891818168A5009653018 @default.
• W2891818168 hasAuthorship W2891818168A5011012477 @default.
• W2891818168 hasAuthorship W2891818168A5012681954 @default.
• W2891818168 hasAuthorship W2891818168A5015970851 @default.
• W2891818168 hasAuthorship W2891818168A5016153923 @default.
• W2891818168 hasAuthorship W2891818168A5026459010 @default.
• W2891818168 hasAuthorship W2891818168A5027981189 @default.
• W2891818168 hasAuthorship W2891818168A5034972183 @default.
• W2891818168 hasAuthorship W2891818168A5043658324 @default.
• W2891818168 hasAuthorship W2891818168A5045301167 @default.
• W2891818168 hasAuthorship W2891818168A5050250195 @default.
• W2891818168 hasAuthorship W2891818168A5051629490 @default.
• W2891818168 hasAuthorship W2891818168A5052487618 @default.
• W2891818168 hasAuthorship W2891818168A5058180553 @default.
• W2891818168 hasAuthorship W2891818168A5062581318 @default.
• W2891818168 hasAuthorship W2891818168A5068059897 @default.
• W2891818168 hasAuthorship W2891818168A5069170386 @default.
• W2891818168 hasAuthorship W2891818168A5069182089 @default.
• W2891818168 hasBestOaLocation W28918181681 @default.
• W2891818168 hasConcept C104317684 @default.
• W2891818168 hasConcept C121608353 @default.
• W2891818168 hasConcept C126322002 @default.
• W2891818168 hasConcept C143998085 @default.
• W2891818168 hasConcept C150194340 @default.
• W2891818168 hasConcept C185592680 @default.
• W2891818168 hasConcept C2776694085 @default.
• W2891818168 hasConcept C2777063308 @default.
• W2891818168 hasConcept C2779733811 @default.
• W2891818168 hasConcept C2780110267 @default.
• W2891818168 hasConcept C530470458 @default.
• W2891818168 hasConcept C55493867 @default.
• W2891818168 hasConcept C71924100 @default.
• W2891818168 hasConcept C90924648 @default.
• W2891818168 hasConceptScore W2891818168C104317684 @default.
• W2891818168 hasConceptScore W2891818168C121608353 @default.
• W2891818168 hasConceptScore W2891818168C126322002 @default.
• W2891818168 hasConceptScore W2891818168C143998085 @default.
• W2891818168 hasConceptScore W2891818168C150194340 @default.
• W2891818168 hasConceptScore W2891818168C185592680 @default.

• next